Development and Validation of a Highly Sensitive RT-qLAMP Assay for Rapid Detection of SARS-CoV-2: Methodological Aspects
Molecular Biotechnology · 2025
DOI: 10.1007/s12033-024-01275-7 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Faezeh Mahmoudi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, 14496114535, Iran. Hauptthemen laut MEDLINE: SARS-CoV-2, Nucleic Acid Amplification Techniques, COVID-19, Molecular Diagnostic Techniques. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Iran University of Medical Sciences.
Abstract (Originalsprache)
Specific and reliable diagnostic methods are becoming increasingly essential to identify patients in light of the high transmission rate and the recent appearance of the new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For the specific detection of SARS-CoV-2, our quantitative reverse transcription loop-mediated isothermal amplification (RT-qLAMP) assay implementation demonstrates how flexible it can be with two readouts: visualized colorimetric and real-time fluorescence. Different factors were optimized to improve the reaction conditions, including temperature (60 °C), assay runtime (60 min), primers, MgSO4 (6 mM), dNTPs (1 mM), LAMP Buffer (1.2 mM Tris-HCl), KCl (50 mM), pH (8), and phenol red (10 mM) concentrations. Regarding analytical sensitivity, the colorimetric RT-LAMP method detected samples with Ct values up to 29, while the RT-qLAMP assay identified up to Ct = 31. RT-qLAMP was evaluated on 40 clinical samples (25 positives and 15 negatives) for viral RNA detection. All negative samples were found negative through fluorescent reading in RT-qLAMP and quantitative reverse transcription PCR (RT-qPCR) assays. Twenty-three clinically positive samples demonstrated a positive RT-qLAMP reaction (up to Ct ≤ 31) with 92% clinical sensitivity, 100% clinical specificity, 100% positive predictive value (PPV), 88.24% negative predictive values (NPV), and 95% accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, 14496114535, Iran.
- Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, 14496114535, Iran. mahmood.barati@gmail.com.
- Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, 14496114535, Iran. neda.s.afshari@gmail.com.
Förderung
- Iran University of Medical Sciences
Zitieren
APA
Mahmoudi, F., Jafari, D., Esfahani, S. M. M., Hoseini, A., Barati, M., & Saraygord-Afshari, N. (2025). Development and Validation of a Highly Sensitive RT-qLAMP Assay for Rapid Detection of SARS-CoV-2: Methodological Aspects. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01275-7
Vancouver
Mahmoudi F, Jafari D, Esfahani SMM, Hoseini A, Barati M, Saraygord-Afshari N. Development and Validation of a Highly Sensitive RT-qLAMP Assay for Rapid Detection of SARS-CoV-2: Methodological Aspects. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01275-7
BibTeX
@article{Mahmoudi2025,
author = {Mahmoudi, Faezeh and Jafari, Davod and Esfahani, Seyedeh Mona Mousavi and Hoseini, Arshad and Barati, Mahmood and Saraygord-Afshari, Neda},
title = {Development and Validation of a Highly Sensitive RT-qLAMP Assay for Rapid Detection of SARS-CoV-2: Methodological Aspects},
journal = {Molecular Biotechnology},
year = {2025},
doi = {10.1007/s12033-024-01275-7}
}
EUVIMED